MedTrace Logo

Prognostic Value of FP-CIT-SPECT in Parkinson´s Disease

NCT01038310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2020-01-28

No results posted yet for this study

Summary

The investigators aim to study whether the nuclear medicine method FP-CIT-SPECT (more details see below) allows to predict the further clinical course of Parkinson´s disease. Especially the investigators are interested in the motor and cognitive functions of the parkinsonian patients.

Conditions

  • Parkinson´s Disease

Sponsors & Collaborators

  • Universität des Saarlandes

    lead OTHER

Principal Investigators

  • Jörg Spiegel, Coordinator · Department of Neurology, Saarland University, Kirrberger Straße, D-66421 Homburg/Saar, Germany

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Germany

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038310 on ClinicalTrials.gov